on March 8, 2018 Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of patients with life-threatening hematologic cancers, reported its financial results for the quarter and year ended December 31, 2017, on Tuesday, March 27, 2018 after the close of the market (Press release, Aptose Biosciences, MAR 8, 2018, View Source;p=RssLanding&cat=news&id=2336995 [SID1234524536]). 

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call & Webcast:
Tuesday, March 27th @ 5:00pm Eastern Time
Toll-Free: (844) 882-7834
International: (574) 990-9707
Passcode: 8873259
Webcast: View Source

Replays available through April 3rd, 2018
Toll-Free: (855) 859 2056
Replay Passcode: 8873259

The live conference call can also be accessed through a link on the Investor Relations section of Aptose’s website at ir.aptose.com. Please log onto the webcast at least 10 minutes prior to the start of the call to ensure time for any software downloads that may be required. An archived version of the webcast along with a transcript will be available on the company’s website for 30 days.

The press release, the financial statements and the management’s discussion and analysis for the quarter ended and year ended December 31, 2017 will be available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml